What’s the financial overview for Novozymes A/S?

Novozymes A/S’s market cap stands at $0.03 trillion right now. The company’s trailing twelve-month earnings per share EPS is $1.42, with a dividend yield of 1.56%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

How can I analyze historical data?

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

What does Novozymes A/S Stock ROE tell us?

Novozymes A/S stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

What is per share price for Novozymes A/S?

The Novozymes A/S stock per share price is $62.46.

Novozymes A/S

NVZMF•PNK

Basic Materials

Chemicals - Specialty

$62.46

$0.97(1.58%)

Novozymes A/S (NVZMF) Financial Performance & Income Statement Overview

Analyze Novozymes A/S (NVZMF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth

-78.58%

↓ 78.58%

Operating Income Growth

-83.43%

↓ 83.43%

Net Income Growth

-89.89%

↓ 89.89%

Operating Cash Flow Growth

-75.44%

↓ 75.44%

Operating Margin

10.20%

↑ 10.20%

Gross Margin

43.95%

↑ 43.95%

Net Profit Margin

5.40%

↑ 5.40%

ROE

1.94%

↑ 1.94%

ROIC

12.30%

↑ 12.30%

Novozymes A/S (NVZMF) Income Statement & Financial Overview

Analyze Novozymes A/S’s NVZMF earnings with segmented quarterly and yearly financial statement figures.

Metric	Q1 2025	Q4 2024	Q2 2024	Q1 2024
Revenue	$1.08B	$2.002B	$6.83B	$6.83B
Cost of Revenue	$483.30M	$959.30M	$3.97B	$3.97B
Gross Profit	$594.30M	$1.04B	$2.86B	$2.86B
Gross Profit Ratio	$0.55	$0.52	$0.42	$0.42
R&D Expenses	$107.30M	$218.70M	$725.39M	$725.43M
SG&A Expenses	$212.30M	$406.00M	$1.34B	$1.34B
Operating Expenses	$328.80M	$607.00M	$2.36B	$2.36B
Total Costs & Expenses	$812.10M	$1.57B	$6.33B	$6.33B
Interest Income	$0.00	$0.00	$0.00	$0.00
Interest Expense	$0.00	$0.00	$0.00	$0.00
Depreciation & Amortization	$0.00	$0.00	$292.31M	$292.25M
EBITDA	$275.70M	$435.50M	$1.13B	$1.13B
EBITDA Ratio	$0.26	$0.22	$0.16	$0.16
Operating Income	$265.50M	$435.50M	$503.49M	$503.51M
Operating Income Ratio	$0.25	$0.22	$0.07	$0.07
Other Income/Expenses (Net)	-$20.80M	-$108.40M	-$167.83M	-$167.84M
Income Before Tax	$244.70M	$327.10M	$335.66M	$335.67M
Income Before Tax Ratio	$0.23	$0.16	$0.05	$0.05
Income Tax Expense	$58.70M	$85.20M	$97.34M	$97.35M
Net Income	$186.00M	$241.90M	$238.32M	$238.33M
Net Income Ratio	$0.17	$0.12	$0.03	$0.03
EPS	$0.40	$0.53	$0.86	$0.86
Diluted EPS	$0.40	$0.53	$0.86	$0.86
Weighted Avg Shares Outstanding	$465.00M	$456.42M	$277.90M	$277.90M
Weighted Avg Shares Outstanding (Diluted)	$465.00M	$456.42M	$277.90M	$277.90M

Financial performance has remained strong, with revenue growing from $6.83B in Q1 2024 to $1.08B in Q1 2025. Gross profit continued to perform well, with margins at 55% in the latest quarter. Operating income reached $265.50M in Q1 2025, holding a steady 25% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $275.70M. Net income dropped to $186.00M, keeping EPS at $0.40. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;